Abstract: Infl iximab is a monoclonal antibody that targets tumor necrosis factor-α (TNFα). It is used in the treatment of a number of infl ammatory disorders including severe plaque psoriasis. TNFα is thought to have a major role in psoriasis by promoting an infl ammatory infi ltrate into the skin and inducing keratinocyte proliferation and preventing keratinocyte apoptosis, which directly contributes to the characteristic plaque skin lesions. Based on four randomized, placebo-controlled, double-blind clinical trials and nine open-label uncontrolled trials of the use of infl iximab in plaque psoriasis, it was found that infl iximab is a highly effi cacious, rapid, sustainable, and relatively safe therapy. Yet as with any biologic, caution is recommended in its use as infusion reactions, lupus-like syndromes, infections, malignancies including lymphomas, as well as other rare events have been reported.
Psoriasis is a chronic infl ammatory disease of the skin affecting at least 5.8 million people in the United States and 125 million people worldwide (National Psoriasis Foundation 2007; Gelfand et al 2005) . The most common form of psoriasis, psoriasis vulgaris, occurs in more than 80% of cases. Less common forms include guttate psoriasis and erythrodermic and pustular psoriasis, which occur in approximately 10% and 3% of patients, respectively (Lebwohl 2003) . Psoriatic lesions may be pruritic and disfi guring, resulting in a signifi cant negative physical and emotional impact in those affected. Feelings of depression, fear and embarrassment, as well as dissatisfaction with disease management, are widespread among persons suffering from psoriasis (Krueger et al 2001) . In 10%-30% of psoriatic patients, nail dystrophy and psoriatic arthritis cause interference with many daily activities that require both fi ne and gross motor skills (Nickoloff and Nestle 2004) . Psoriasis cannot be explained purely by genetics (Elder et al 2001) or environment; it has a complex immunopathology that is not fully understood.
Immunopathology of psoriasis
Psoriasis results from an abnormal activation of the immune system, with T cells in the epidermis and dermis playing a central role. The initial activation of T cells is unclear, but is thought to be due to a protuberance in epidermal keratinocytes from exogenous stimuli such as trauma and UV exposure, or endogenous stimuli such as infection and medications (eg, lithium and β-blockers) which through a "danger signal" leads to the activation of antigen presenting cells (APCs) such as Langerhans cells (Matzinger 2002; Nickoloff and Nestle 2004) . Once activated, Langerhans cells migrate through the lymphatic system to surrounding lymph nodes where its MHCantigen complex is recognized by specifi c T cell receptors on naïve T cells. Full activation of T cells occurs with a costimulatory molecule on APCs combining with CD28 on T cells. The activated T cell expresses cutaneous lymphocyte-associated antigen (CLA) which allows access to the skin (Langley et al 2007) . The abnormally activated T cells elaborate cytokines including tumor necrosis factor-α (TNFα) and γ-interferon which contribute to a vicious cycle of infl ammation and tissue damage, manifested clinically as plaque skin lesions (Nickoloff 1991) .
Role of TNFα in psoriasis
TNFα is found in high concentrations in the skin lesions and plasma of patients with psoriasis and has a major role in the stimulation and propagation of immunological activity by targeting an infl ammatory infi ltrate into the skin (Turbitt et al 1990) . TNFα upregulates the expression of vascular endothelial growth factor (VEGF) and intercellular adhesion molecule-1/vascular cell adhesion molecule-1 which promotes angiogenesis and microvascular permeability and targeting of lymphocytes to infl ammatory lesions, respectively (Markham et al 2006) . TNFα induces Langerhans cell maturation and migration to lymph nodes for further T cell activation and CLA expression. TNFα further stimulates lymphocyte migration, increasing the expression of many proinfl ammatory cytokines including CCL27 (a skin-specifi c memory T cell attractant) and NF-kB (a ubiquitous transcription factor) that leads to the expression of many gene products that mediate infl ammatory responses (Banno et al 2004) .
TNFα directly contributes to the characteristic plaque surmounted by silvery scales by inducing keratinocyte proliferation and preventing keratinocyte apoptosis via increasing vasoactive intestinal peptide (VIP) receptor and increasing plasminogen activator inhibitor type 2, a serine protease inhibitor, respectively (Gottlieb 2003) .
The advances in the understanding of T cells and specifi cally TNFα in psoriasis has led to the development of biologic agents that target them (Sauder and Mamelak 2004; Chong and Wong 2007; Langley et al 2007) .
Infl iximab
Infl iximab is a chimeric monoclonal antibody comprised of human antibody constant regions and murine variable regions that was developed to specifi cally target TNFα. Infl iximab binds both soluble and membrane-bound TNFα, preventing it from binding its receptor which results in a decrease in epidermal T cell infi ltration. There is a signifi cant reduction of T cells in the epidermis of psoriatic lesions after 48 hours of treatment with a single, low dose (3 mg/kg) infusion of infl iximab (Goedkoop et al 2004) .
Infl iximab helps to control angiogenesis, a key factor in the proinfl ammatory state of psoriasis, by down-regulating angiopoietin, a growth factor critical for new blood vessel growth, and its receptor, Tie2 (Markham et al 2006) .
Furthermore, anti-TNFα drugs like infl iximab have been shown to restore neuroendocrine pathways (eg, hypothalamic -pituitary -adrenal axis) from the pro-infl ammatory state that TNFα favors, and normalizes hormone levels (Straub et al 2006) .
Complementary to its anti-infl ammatory effect that is mediated through the neutralization of TNFα, infl iximab normalizes keratinocyte differentiation and induces apoptosis of lesional keratinocytes through a caspase independent mechanism to further speed clinical improvement (ten Hove et al 2002; Kruger-Krasagakis et al 2006) .
Infl iximab is used to treat a number of infl ammatory disorders including rheumatoid arthritis, Crohn's disease, and psoriatic arthritis (Markham and Lamb 2000; Woolacott et al 2006; Behm and Bickston 2007) . In September 2006, the US FDA approved the use of infl iximab in adults with chronic, severe plaque psoriasis (FDA 2006) . This paper aims to review the effi cacy and safety of infl iximab in this setting based on a plethora of recently published research on the topic.
Randomized, placebo-controlled, double-blind clinical trials
Four randomized, controlled trials of infl iximab in the treatment of plaque psoriasis have been reported in the literature (Table 1) . Chaudhari and colleagues (Chaudhari et al 2001; conducted a small (n = 33), phase II trial consisting of a patient population with moderate to severe plaque psoriasis involving a minimum of 5% body surface area (BSA) for at least 6 months. The patients were randomly assigned to one of three groups: 5 mg/kg infl iximab (n = 11), 10 mg/kg infl iximab (n = 11), or placebo (n = 11). Infusions were given at 0, 2, and 6 weeks and followed by an open-label phase from weeks 10-26 in which relapsing patients were retreated as needed and placebo nonresponders were given an induction of infl iximab. Beginning at week 2, the improvement in PASI (Psoriasis Area and Severity Index) scores were signifi cantly (p Ͻ 0.0003) higher in both infl iximab treated groups. At week 10, the PASI 75 (at least 75% improvement from baseline in PASI) was achieved in 82% and 73% of patients receiving 5 mg/kg and 10 mg/kg infl iximab, respectively, compared to only 18% of placebo patients (p Ͻ 0.05). PASI 75 was maintained in 33% and 67% of the respective infl iximab patients through week 26. Infusion reactions occurred in 9% of patients, but no other autoimmune events were reported. Reported adverse events (AE) were considered mild by the investigator and no serious adverse events (SAE) occurred.
Infl iximab for plaque psoriasis A larger (n = 249) phase II trial was conducted by Gottlieb and colleagues (Gottlieb et al 2004; Feldman et al 2005) that consisted of a study population with severe plaque psoriasis covering at least 10% BSA for 6 months or more and a PASI of at least 12. Patients were randomly assigned to either a 3 mg/kg infl iximab (n = 99), 5 mg/kg infl iximab (n = 99), or placebo (n = 51) treatment group with infusions given at 0, 2, 6 weeks, and an additional one at week 26 if a static Physician's Global Assessment (PGA) of moderate to severe psoriasis was made. At week 10, PASI 75 was achieved in 72% and 88% of 3 mg/kg and 5 mg/kg infl iximab patients, respectively, compared to only 6% of placebo treated patients (p Ͻ 0.001). In two of the aforementioned studies (Chaudhari et al 2001; Gottlieb et al 2004) , no signifi cant differences were recorded between the two infl iximab groups in inducing signifi cant clearance, but larger dose infl iximab groups, 10 mg/kg and 5 mg/kg, respectively, maintained remission longer. The Dermatology Life Quality Index (DLQI) at week 10 was improved by 84% and 91%, respectively, in infl iximab treated patients compared to 0% in the placebo group (p Ͻ 0.001). AE and SAE were reported in 78% and 4% of the 3 mg/kg patients, 79% and 8% of the 5 mg/kg patients, and 63% and 0% of the placebo patients, respectively. The lower percentage of AE in the placebo group could be partly a result of the high dropout rate in the placebo group and thus shorter follow-up. Yet four of the SAE in the infl iximab groups -squamous cell carcinoma, cholecystitis and cholelithiasis, diverticulitis, and sepsis and pyelonephritis -were considered by the investigator to be reasonably related to infl iximab therapy. Infusion reactions were reported in 18% and 22% of patients in the infl iximab groups, respectively, compared to 2% of the placebo group. Through week 26, 24% patients with antibodies to infl iximab experienced infusion reactions compared to 22% antibody-negative patients The only noteworthy elevated lab values were the liver function tests (LFTs) aminotransferase (ALT) and aspartate aminotransferase (AST) in the infl iximab groups (34% and 24%, respectively) compared to placebo (16% and 14%, respectively) Reich et al (2005) reported the fi rst multicenter phase III study of infl iximab [European Infl iximab for Psoriasis (Remicade) Effi cacy and Safety Study/EXPRESS] in patients (n = 378) with moderate to severe plaque psoriasis of at least 10% BSA and 6 month duration with PASI of 12 or more. Patients were randomly placed into a 5 mg/kg infl iximab or placebo group with infusions given at 0, 2, and 6 weeks and then every 8 weeks through week 46. At week 24, placebo patients were crossed to receive infl iximab. At week 10 and 24, PASI 75 was achieved in 80% and 82% of infl iximab patients, but only 3% and 4% of placebo patients, respectively (p Ͻ 0.0001). At week 50, PASI 75 was achieved in 61% of infl iximab-treated patients. There was generally good tolerability to infl iximab with AE and SAE at week 24 reported in 82% and 6% of infl iximab-treated patients and 71% and 3% placebo-treated patients, respectively. With equal follow-up, similar proportions of patients in the infl iximab and placebo groups were diagnosed with infections, but serious infections were more prevalent in the infl iximab group. Malignancies, squamous and basal cell carcinomas, occurred in 1% of infliximab-treated patients but 0% in placebo-treated patients. In infl iximab-treated patients, 3% had infusion reactions (2% in the placebo-treated patients) and two patients had a lupus-like syndrome. No clinically signifi cant changes in hematological values were noted except for asymptomatic increases in AST and ALT. Menter et al (2007) performed the largest phase III trial to date (n = 835) with moderate to severe plaque psoriasis covering at least 10% BSA and PASI of 12 or more (Evaluation of Infl iximab for Psoriasis in a Remicade Effi cacy and Safety Study/EXPRESS II). Study participants were randomly assigned to a 3 mg/kg (n = 313), 5 mg/kg (n = 314), or placebo (n = 208) group with infusions at 0, 2, and 6 weeks. At week 14, the two infl iximab groups were re-randomized to either 8 week continuous or intermittent as-needed therapy. At week 10, PASI 75 was achieved in 70% and 76% of the 3 mg/kg and 5 mg/kg infl iximab-treated patients, respectively, but only 2% of placebo-treated patients (p Ͻ 0.001). At week 50, PASI 75 was achieved in 44% of the 3 mg/kg continuous group compared to 25% of the intermittent group, and 55% of the 5 mg/kg continuous group compared to 38% of the intermittent group. At week 10, both infl iximab groups had a signifi cant improvement in DLQI (p Ͻ 0.001). AE and SAE at week 14 occurred in 63% and 1.0% of the 3 mg/kg infl iximab group and 69% and 2.9% of the 5 mg/kg infl iximab group compared to 56% and 2.4% of the placebo group, respectively. Through week 14, 12% and 10%, in the infl iximab groups, respectively, experienced an infusion reaction compared to 6% in the placebo group. While the majority of antibody-positive patients did not have an infusion reaction, an increased risk of a reaction was present in these patients compared to antibodynegative patients. Two cases of lupus-like syndrome occurred in the infl iximab group compared to one in the placebo group (2:1 randomization of infl iximab to placebo). Infection rates were similar in infl iximab and placebo groups. Noteworthy adverse events in the infl iximab group involved 2 cases of TB, 12 malignancies (1 breast carcinoma, 1 salpingeal Infl iximab for plaque psoriasis adenocarcinoma, 1 squamous cell skin carcinoma, and 9 basal cell skin carcinomas) compared to 0 in the placebo group, and a signifi cant elevation of ALT and AST in fewer than 5% of infl iximab-treated patients.
Open-label, uncontrolled trials
Nine open-label, uncontrolled trials of 5 mg/kg infl iximab in the treatment of psoriasis have been reported (Table 2) . In all trials, the majority of patients presented with plaque psoriasis but patients with erythrodermic and pustular psoriasis, acrodermatitis continua, and psoriatic arthritis are also included, and the patient population ranges from n = 7 to n = 73. Chan and Gebauer (2003) demonstrated that a single 5 mg/kg infusion provided an average PASI and DLQI improvement at week 2 of 69% and 61%, respectively, and at week 10 (n = 4) of 89% and 79%, respectively, with no SAE reported.
In all the other open label studies 5 mg/kg infusions were given at a minimum of 0, 2, and 6 weeks. (Schopf et al 2002) demonstrated an average PASI improvement of 88% (n = 8) at week 14. PASI 75 at week 10 was achieved in 79% (Cassano et al 2004) and 77% of patients (Smith et al 2006) in trials consisting of 29 and 23 patients, respectively. At week 14, PASI 75 was achieved in 68% of patients in a trial of 28 patients (Poulalhon et al 2007) . The magnitude of clinical improvement in the trials that reported PASI scores were similar to the randomized, controlled trials with PASI 75 at week 10 achieved in 76% to 88% of patients receiving 5 mg/kg infusions in these trials (Table 1) .
Three trials measured improvement on the PGA scale: the fi rst reported 88% of patients achieving almost clear improvement or better (n = 52) (Kalb and Gurske 2005) ; a second reported 75% of patients achieving excellent improvement (n = 12) (Ahmad and Rogers 2006) ; and a third reported 89% of patients achieving signifi cant improvement after 12-14 weeks of treatment (Haitz and Kalb 2007) . Krathen et al (2006) reported that 51% of patients experienced no loss of effi cacy, while 30% of patients experienced a loss of effi cacy, and others discontinued their participation in the clinical trials due to adverse events or insurance diffi culties.
AE were similar to those in the randomized, controlled trials with infusion reactions and infections being the most prevalent (Table 2) . Serious infections included extrapulmonary tuberculosis, cellulitis (Smith et al 2006) , sepsis, pneumonia, and chronic obstructive pulmonary disease (COPD) (Poulalhon et al 2007) . Two studies reported elevated LFTs (Ahmad and Rogers 2006; Smith et al 2006) , and one patient with a prior history of fatty liver secondary to methotrexate and alcohol was diagnosed with autoimmune hepatitis caused by infl iximab (Smith et al 2006) . Reported malignancies included single cases of breast cancer (Krathen et al 2006) , skin cancer, metastatic renal cell carcinoma, and CD30+ cutaneous T cell lymphoma (Smith et al 2006) . The latter occurred in a 56-yearold man with a 30-year history of immunosuppressive therapies including cyclosporine, methotrexate, alefacept, and fumaric acid esters after 3 infusions of infl iximab.
Effi cacy
The aforementioned clinical trials (Tables 1 and 2) demonstrate that infliximab provides a rapid (as early as 2 weeks) (Chaudhari et al 2001) , highly effi cacious, and sustainable (up to 50 weeks) therapy especially when given at continuous (8-week) maintenance intervals (Menter et al 2007) for the treatment of moderate to severe plaque psoriasis. Infl iximab use leads to a signifi cant improvement in the quality of life as assessed by DLQI in those affected by psoriasis (Gottlieb et al 2004; Menter et al 2007) . This is a very important fi nding considering that psoriasis has an impact on an affected persons' physical and mental functioning comparable to that seen in cases of cancer, arthritis, hypertension, heart disease, diabetes, and depression (Rapp et al 1999) .
Safety
Infl iximab is generally well tolerated; infusion reactions are the most commonly reported adverse events, occurring in 16% infl iximab-treated patients compared to 6% of placebotreated patients (Callen 2007) . Infusion-related reactions can involve chills, fever, headache, fl ushing and urticaria, myalgia and arthralgia, nausea, dyspnea, and hypotension (Gottlieb et al 2004; Reich et al 2005; Menter et al 2007) . Most infusion-related reactions are mild and usually can be ameliorated by reducing rate of infusion rather than discontinuing therapy. A delayed hypersensitivity reaction may also present 3-12 days after infusion and produce a serumsickness like reaction (Krishnan and Hsu 2004) .
Acute and delayed hypersensitivity reactions are partly the result of autoantibody formation towards infl iximab, a concern related to the infusion of any foreign protein (Schellekens 2002) . Patients with infl iximab antibodies have been shown to be more likely to have an infusion reaction when compared to those with no antibodies (Menter et al 2007) . However the strength of this relationship is not defi nitive (Gottlieb et al 2004) , and even the proportion of infusion reactions in infl iximab and placebo groups have shown to be similar (Reich et al 2005) . This issue requires further 
47% experienced minor infections
Abbreviations: AE, adverse events; BSA, body surface area; DLQI, Dermatology Life Quality Index; COPD, chronic obstructive pulmonary disease; GI, gastrointestinal; PASI, Psoriasis Area and Severity Index; PGA, physician's global assessment; PsA, psoriatic arthritis; LFTs, liver function tests; SAE, serious adverse events; TB, tuberculosis.
investigation but the potential for subsequent reactions during infusion demands close monitoring. Another concern related to formation of antibodies to infl iximab is the decreased effi cacy of infl iximab over time which may require increased infusion frequencies or higher doses to maintain a clinical response and disease control (Haitz and Kalb 2007; Shear 2006) . Patients with neutralizing antibodies are less likely to maintain a response to infl iximab than those negative for antibodies, but this does not determine clinical responsiveness (Reich et al 2005; Menter et al 2007) . When infl iximab is used in the treatment of Crohn's disease, there is a signifi cant correlation between the development of antibodies against infl iximab and increased risk of infusion reactions and shorter duration of response (Schellekens 2002) . This relationship is much less clear in the treatment of plaque psoriasis as no randomized, placebo-controlled trials have been performed to date. From our experience, the frequency of infl iximab administration for the treatment of plaque psoriasis should be based on clinical response rather than antibody status. We have found that when the clinical response to infl iximab is waning, increasing the frequency of infl iximab infusions is more effective than the addition of low dose methotrexate.
TNFα inhibition is associated with a lupus-like syndrome, which is also thought to be partly the result of an antibody response following infl iximab infusion (Costa et al 2007; Ramos-Casals et al 2007) . In the aforementioned randomized, controlled trials of 378 (Reich et al 2005) and 835 (Menter et al 2007) patients with psoriasis, two patients in each study had a lupus-like syndrome. It should be noted that in the latter case, one patient in the placebo group was diagnosed with the syndrome with a 2:1 randomization of infl iximab to placebo (Menter et al 2007) .
Infl iximab's anti-TNFα effects hamper the immune system's role in defense against infections and malignancies. In the clinical use of infl iximab, infection is the chief concern with upper respiratory infections being the most common Reich et al 2005; Menter et al 2007) . In the randomized, controlled clinical studies, there is no clinically signifi cant increase in infection risk with infl iximab compared to placebo (Reich et al 2005; Menter et al 2007) . Yet, serious infections (Reich et al 2005) and malignancies (Gottlieb et al 2004; Reich et al 2005; Menter et al 2007) are more prevalent in the infl iximab groups, demonstrating the importance of monitoring for malignancy and infection. No additional safety concerns are found for the 5 mg/kg dose compared to the 3 mg/kg dose (Menter et al 2007) .
In individuals undergoing infl iximab therapy for a variety of autoimmune disorders, serious infections have been seen with the following agents: Pneumocystis jiroveci, Mycobacterium tuberculosis, Listeria monocytogenes, Candida albicans, Aspergillus fumigatus, Histoplasma capsulatum, Cryptococcus neoformans, and Coccidioides immitis -infections typical of the immunocompromised (Ellerin et al 2003; Kaur and Mahl 2007) . A case of osteomyelitis in a patient without a history of trauma who received infl iximab therapy for severe psoriasis and psoriasis arthritis has recently been reported (Sri et al 2007) .
Specifi cally, tuberculosis is a concern as TNFα plays a central role in defense against mycobacterial infections and containment of existing infections (Gardam et al 2003) . The reactivation of latent tuberculosis is a well-known complication of infl iximab therapy. A review of 70 cases of tuberculosis that developed after the initiation of treatment with infl iximab found that the majority (56%) of patients present with extrapulmonary tuberculosis while 24% had disseminated disease, forms of tuberculosis associated with immunosuppression (Keane et al 2001) . These results have been reaffi rmed in subsequent clinical trials (Krathen et al 2006; Smith et al 2006) . This atypical presentation as well as higher incidence of extensive infection underlines the importance of screening for tuberculosis prior to therapy by patient history, a tuberculin skin test, a chest radiograph, and maintaining a high degree of clinical suspicion throughout treatment.
MedWatch received 8 reports of lymphoma in approximately 121,000 patients (6.6/100,000) that used infliximab between May 1999 and December 2000 for rheumatoid arthritis (RA) and Crohn's disease (CD), with the lymphomas occurring within a median of 6 weeks after initiation of therapy (Brown et al 2002) . It is unclear whether the lymphomas developed directly from the use of infl iximab, pre-existing medical conditions, or other immunosuppressive agents that the patients were receiving. The aforementioned clinical trials of infl iximab in the treatment of psoriasis documented a single case of CD30+ cutaneous T cell lymphoma in a patient previously treated with multiple immunosuppressive therapies (Smith et al 2006) . Thus, the majority of data supporting a relationship between infl iximab therapy and lymphoma risk comes from RA and CD patients. The risk of lymphoma in psoriasis patients treated with infl iximab has not clearly been established.
Clinical trials have demonstrated a slight increase in malignancy in patients treated with infl iximab. The two largest randomized, controlled clinical trials of infl iximab in the treatment of psoriasis found 2% (Menter et al 2007) and 1% (Reich et al 2005) of 627 and 298 infl iximab-treated patients experiencing a malignancy, respectively, compared to 0 in placebo-treated patients, the majority being skin cancers. However, long-term registry data with larger numbers of patients have not shown an association between biologic therapy and the development of solid tumors or lymphoma. There is an association with skin cancers in this registry group (Wolfe and Michaud 2007) .
Much of the evidence supporting a relationship between malignancy and TNFα antagonist therapy is derived from the treatment of rheumatoid arthritis patients. A cohort study of patients treated with biologic disease-modifying antirheumatic drugs (DMARDs) including etanercept, infl iximab, adalimumab, and anakinra for rheumatoid arthritis found 11 hematologic malignancies and 46 solid tumors during 2940 person-years of DMARD use, and a pooled hazard ratio of 1.37 (95% confi dence interval, 0.71-2.65) and 0.91 (95% confi dence interval, 0.65-1.26) for the respective malignancies when compared to methotrexate-treated patients (Setoguchi et al 2006) . A review of nine randomized, placebocontrolled trials of the use of infl iximab or adalimumab in the treatment of rheumatoid arthritis found a dose-dependent increased risk of malignancy in patients treated with anti-TNF antibody therapy compared to placebo with a pooled odds ratio for malignancy of 3.3 (95% confi dence interval, 1.2-9.1) (Bongartz et al 2006) .
Preliminary experimental evidence suggested a link between elevated TNFα and congestive heart failure (CHF) and that inhibition of TNFα could favorably modify the course of the disease (Torre-Amione et al 1996 ; Feldman et al 2000) . This theory was discounted when three largescale clinical trials of the TNFα inhibitors, infl iximab (Chung et al 2003a) and etanercept (Anker and Coats 2002) , used in the treatment of CHF were halted for lack of benefi t or adverse outcomes. The infl iximab trial revealed that shortterm infl iximab therapy did not improve patients with CHF, and high doses (10 mg/kg) adversely affected patients with CHF (p = 0.043) (Chung et al 2003b) . MedWatch data also suggest that TNFα antagonists may induce heart failure in certain patients (Kwon et al 2003) . No adverse cardiac events were reported in the trials of patients receiving infl iximab therapy for psoriasis (Tables 1 and 2) .
Infl iximab is associated with cases of central nervous system involvement including rare demyelinating disorders (Mohan et al 2001; Robinson et al 2001) . The clinical trials of infl iximab in the treatment of psoriasis found that no cases of CNS disease resulted from this therapy (Tables 1  and 2 ). The causal relationship is weak if it exists at all, but it is recommended that the use of infl iximab and other TNFα antagonists be avoided in patients with a history of demyelinating disease, and that therapy be discontinued when neurologic symptoms occur.
Elevations in serum ALT and AST are fairly commonly reported (Tables 1 and 2 ), but associated hepatobiliary problems are much less frequent. In a letter to healthcare professionals regarding the potential of hepatotoxicity due to infliximab therapy, the US FDA reported 35 post-marketing and 3 clinical trial events of severe hepatitic reactions including acute liver failure, jaundice, autoimmune hepatitis, and cholestasis (Important drug warning 2004). In clinical trials of the use of infl iximab in plaque psoriasis reviewed here (Tables 1 and 2 ), a single case of autoimmune hepatitis due to infl iximab was reported in a patient previously diagnosed with fatty liver (Smith et al 2006) . Hepatitis has also been reported in a patient undergoing infl iximab therapy for psoriasis in the absence of autoimmune disease and previous liver damage (Wahie et al 2006) . In both patients, previous methotrexate use and alcohol consumption are contributing factors. It is thought that concurrent methotrexate and infl iximab therapy may exert synergistic effects on liver function, underlying the importance of close monitoring of liver function tests, especially in patients with a history of methotrexate use and alcohol consumption.
The extensive clinical trials and cases referenced above as well as physician experience has allowed the detection of the aforementioned rare adverse events. More long-term safety data has to be collected to establish a defi nitive relationship between these adverse events and infl iximab in the treatment of psoriasis. Infl iximab has generally been well tolerated in the more than 924,000 patients that have received infusions (Remicade 2007) .
